View in EDS

Class II Peptide-Major Histocompatibility Complex Lipid Nanoparticles Enable in vivo mRNA Delivery to Antigen-Specific CD4+ T Cells.

Saved in:
Bibliographic Details
Title: Class II Peptide-Major Histocompatibility Complex Lipid Nanoparticles Enable in vivo mRNA Delivery to Antigen-Specific CD4+ T Cells.
Authors: Choy J; Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Translational Therapeutic and Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Cheng L; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Translational Therapeutic and Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Patel M; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Translational Therapeutic and Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Zhu Y; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Translational Therapeutic and Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Ma J; Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Translational Therapeutic and Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Kang SS; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Jain M; Translational Therapeutic and Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Biggs BA; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Schneck JP; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States., Mao HQ; Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland 21218, United States.; Translational Therapeutic and Regenerative Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Center for Translational ImmunoEngineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.
Source: ACS applied materials & interfaces [ACS Appl Mater Interfaces] 2026 Feb 11; Vol. 18 (5), pp. 7818-7829. Date of Electronic Publication: 2026 Feb 02.
Publication Type: Journal Article
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101504991 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1944-8252 (Electronic) Linking ISSN: 19448244 NLM ISO Abbreviation: ACS Appl Mater Interfaces Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1944-8252
DOI:10.1021/acsami.5c21115